Dr. Landon Chan
Specific Research / Sites of Interest
• Hepatobiliary and pancreatic cancer; gastrointestinal cancer
• Oligometastatic and oligoprogressive disease
• Synergism of radiotherapy with immunotherapy and other novel therapeutics
Short Biography
Dr. Landon Chan is a clinical oncologist by training. He joined the Department of Clinical Oncology at the Chinese University of Hong Kong as an Assistant Professor (clinical) in 2023. Prior to his career in medicine, he was trained as a Mathematician and received his Bachelor of Arts from Carleton College in Minnesota, United States. After working at the Mayo Clinic for one year as a statistical analysis programmer, he returned to Hong Kong to pursue his career in clinical medicine. He obtained his medical degree from the Chinese University of Hong Kong in 2017 and became a fellow of the Royal College of Radiologists in 2022. He received a MSc degree in Precision Cancer Medicine from Oxford University in 2022 and became a fellow of the Hong Kong College of Radiologists in 2025.
Dr. Landon Chan has a long history of interest in personalized medicine. Fully convinced of the potentials of using sequencing technology to understand tumour biology and hence tailor-made personalized treatment, he has participated in multiple bioinformatics projects in renowned international research groups, including Prof. Dennis Lo’s and Prof. Kevin Yip’s group at the Chinese University of Hong Kong, Prof. Mark Gerstein’s group at the Yale University, and Prof. Francesca Buffa and Dr. Simon Lord’s group at the Oxford University, with hands-on experience on DNA-seq and RNA-seq data.
His current research interest includes clinical and translational studies on hepatopancreatico-biliary, and how to combine radiotherapy and immunotherapy as part of a personalized therapeutic treatment strategy.
Awards
• Hong Kong College of Radiologists 15A Travelling Fellowship (2026)
• Hong Kong Society of Clinical Oncology Award, best proffered paper, 33rd Annual Scientific Meeting of Hong Kong College of Radiologists (2025)
• Silver Medal for the 2024 Best Original Research by Trainees, Hong Kong Academy of Medicine (2024)
• Central Conference Grant by the Chinese University of Hong Kong (2024)
• ESMO Asia 2023 Travel Grant for Young Oncologists (2023)
Professional and Community Services
• Subcommittee member (International), Hong Kong Society of Radiation Oncology, since April 2026 - present
• Council member, Hong Kong Society of Digestive Oncology, since September 2025 - present
Grants
• PI, Health and Medical Research Fund 2023/2024, Stereotactic Body Radiotherapy with Immunotherapy (Atezolizumab plus Bevacizumab) in Patients with Advanced HCC and Major Portal Vein Tumour Thrombosis, 9/2025-9/2028
• PI, Direct Grant for Research 2023/24, Fragmentomics of ctDNA for patients with hepatocellular carcinoma undergoing stereotactic body radiotherapy, CUHK, 06/2024-06/2026
• PI, General Research Fund (Early Career Scheme) 2026/2027, Comprehensive Qualitative and Quantitative Assessment of the Prognostic Role of Circulating Cell-free DNA in Patients with Hepatocellular Carcinoma Receiving Radiotherapy, 01/2027-12/2029
Presentations and Talks
Local Presentations
• Hepato-Pancreato-Biliary Cancer Updates, Summer Oncology Summit 2.0, Hong Kong Cancer Therapy Society, Hong Kong SAR, 07/2026
• Combination of locoregional therapies and immunotherapy for HCC, Immuno-Oncology Hong Kong, Hong Kong SAR, 11/2024
• Experiences on downstaging HCC for curative treatment, ILCA – Roche Preceptorship Programme, Hong Kong SAR, 11/2024
• The recent update of EBRT, ILCA – Roche Preceptorship Programme, Hong Kong SAR, 11/2024
• Role of TKI in the Era of Immunotherapy in Hepatocellular Carcinoma and Case Sharing, Hepatocellular Carcinoma Scientific Meeting, Hong Kong SAR, 10/2024
• BTC Management and Case Sharing & Panel discussion on “HCC & BTC Clinical Management”, HIMALAYA and TOPAZ-1 Launching Symposium, Hong Kong SAR, 07/2024
• Biomarker for HCC surveillance: Beyond AFP, International Liver Cancer Association (ILCA) School of Liver Cancer 2023, Hong Kong SAR, 06/2024
International Presentations
• The evolving role of atezolizumab and bevacizumab in the treatment of HCC. HCC Expert Insights: Redefining Success in HCC Treatment. Bangkok, 07/2026
• Any role for radiotherapy in the intermediate stage. ESMO Asia, Singapore, 12/2025
• Understanding the terminology and modality of radiation. ILCA Pre-conference Masterclass, Hong Kong SAR, 11/2025
• Precision radiation therapy in China: SBRT and immunotherapy. The Belt and Road International Training Course for Precision Radiation Oncology, Shanghai, 09/2025
• Multi-Modality Approaches: Combining Immunotherapy with Other Treatment Modalities, Oncology Expert Congress, Manila, 06/2025
• Co-joint effect of hepatitis B and MASLD in the development of HCC and implications of therapy, 2024 Chinese Congress on Holistic Integrative Oncology, Xian, 11/2024
• Treatment sequencing after immunotherapy for HCC, 2024 TLCA Post ASCO-APPLE Conference, Taipei, 08/2024
• Pemigatinib in Cholangiocarcinoma Scientific Background, Preclinical & Clinical Data, Treatment Landscapes by PD-1 and FGFR Inhibitors, Macau Oncology Association and Innovent Biologics (HK) Limited, Macau, 06/2024
• Locoregional Therapy in Combination with Systemic Therapy in Hepatocellular Carcinoma, 2023 Shanghai Hong Kong Liver Cancer MDT Exchange Conference, Shanghai, 06/2023
Educational Presentations
• Hepatocellular Carcinoma, CUHK Diploma in Advances in Medicine 2026-2027, Hong Kong SAR, 08/2026
• 肝癌精準治療新方向及藥物資助講座, Hong Kong Health Care Alliance, Hong Kong SAR, 07/2026
• Hepatocellular Carcinoma, CUHK Diploma in Advances in Medicine 2024-2025, Hong Kong SAR, 08/2024
Most Representative Publications
| 1. Fortuny M, Chan LL, Da Fonseca LG, Abou-Alfa GK, Chan SL, Reig M. Beyond second-line therapy: Strategic sequencing of systemic treatments in advanced hepatocellular carcinoma. Hepatology. 2026 Jun 8. PMID: 42289095. (IF: 18.0) |
| 2. Chan LL, Chok KSH, Ip AYH, Poon DMC, Chan SL. Recent Advancements in Radiotherapy for Hepatocellular Carcinoma. ESMO Gastrointestinal Oncology. 2026 Mar;11(100308). PMID: 41994002. (IF: 1.7) |
| 3. Chan LL, Yeung VTY, Mo F, Poon DMC, Tong M, Mok FST, Soo WMT, Lam DCM, Lam BHW, Johnson DR, Wong WKY, Chen ACC, Chan SL. Radiation-induced Lymphopenia is Associated with Survival in Patients with Hepatocellular Carcinoma Treated with Stereotactic Body Radiotherapy. JHEP Rep. 2025 Dec 11;8(4):101709. PMID: 41951273. (IF: 8.7) |
| 4. Chan SL, Sun HC, Xu Y, Zeng H, El-Serag HB, Lee JM, Schwartz ME, Finn RS, Seong J, Wang XW, Paradis V, Abou-Alfa GK, Rimassa L, Kao JH, Zhang BH, Llovet JM, Bruix J, Yip TC, Wong VW, Wong GL, Chan LL, Liu MQ, Gao Q, Shen F, Kelley RK, Cheng AL, Kurosaki M, Toyoda H, Chen WX, Murakami T, Liang P, Zucman-Rossi J, Minami Y, Miyayama S, Wang K, Man K, Hasegawa K, Li Q, Tsuchiya K, Xu L, Chew V, Chow P, Hoshida Y, Lujambio A, Ng IO, Sakamoto M, Park YN, Yau T, Kudo M, Fan J, Zhou J. The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment. Lancet. 2025 Aug 16;406(10504):731-778. PMID: 40744051. (IF: 109.0) |
| 5. Chan SL, Lamarca A, Hsu C, Moreno V, Chan LL, Keenan BP. New targets and new drugs for hepatobiliary cancers. J Hepatol. 2025 Aug 25:S0168-8278(25)02455-9. PMID: 40865646. (IF: 40.1) |
| 6. Chan LL, Kwong TT, Yau JCW, Chan SL. Treatment for Hepatocellular Carcinoma After Immunotherapy. Ann Hepatol. 2025 Jul-Dec;30(2):101781. PMID: 39929474. (IF: 6.2) |
| 7. Chan LL, Chan AWH, Yip TCF, Wong GLH, Ngai AKH, Mo F, Chok SH, Kung JWC, Chu CM, Mok K, Li MSC, Wong VWS, Chan SL. Attenuation of the second peak of bimodal recurrence of HBV-related HCC after curative treatment in the antiviral era. J Hepatol. 2025 Jun 9:S0168-8278(25)02266-4. PMID: 40499818. (IF: 40.1) |
| 8. Chan SL, Ryoo BY, Mo F, Chan LL, Cheon J, Li L, Wong KH, Yim N, Kim H, Yoo C. Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment. J Hepatol. 2024 Aug;81(2):258-264. PMID: 38570034. (IF: 40.1) |
| 9. Lee CK, Yoo C, Hong JY, Park SJ, Kim JW, Tai DWM, Kim H, Korphaisarn K, Tanasanvimon S, Chen SC, Kim JW, Kim I, Kim M, Choo J, Oh SB, Chen CT, Bae WK, Kim H, Huh SJ, Yen CJ, Park S, Lee DK, Chan LL, Kang B, Kang M, Sundar R, Choi HJ, Chan SL, Chon HJ, Lee MA. Real-World Study of Systemic Treatment after First-Line Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma in Asia-Pacific Countries. Liver Cancer. 2024 Aug 20;14(2):127-141. PMID: 40255875. (IF: 10.5) |
| 10. Chan LL, Mok K, Chan SL. Radiotherapy following intrahepatic progression on immunotherapy in advanced hepatocellular carcinoma. J Hepatol. 2024 Jun;80(6):e282-e283. PMID: 38242325. (IF: 40.1) |
| 1. Sethi A, Gu M, Gumusgoz E, Chan LL, Yan KK, Rozowsky J, Barozzi I, Afzal V, Akiyama JA, Plajzer-Frick I, Yan C, Novak CS, Kato M, Garvin TH, Pham Q, Harrington A, Mannion BJ, Lee EA, Fukuda-Yuzawa Y, Visel A, Dickel DE, Yip KY, Sutton R, Pennacchio LA, Gerstein M. Supervised enhancer prediction with epigenetic pattern recognition and targeted validation. Nat Methods. 2020 Aug;17(8):807-814. PMID: 32737473. (IF: 28.3) (authors 4 out of 25) |
| 2. Yip DK*, Chan LL*, Pang IK, Jiang W, Tang NLS, Yu W, Yip KY. A network approach to exploring the functional basis of gene-gene epistatic interactions in disease susceptibility. Bioinformatics. 2018 May 15;34(10):1741-1749. PMID: 29329369. *Contribute equally (IF: 5.5) |
| 3. Chan LL, Jiang P. Bioinformatics analysis of circulating cell-free DNA sequencing data. Clin Biochem. 2015 Oct;48(15):962-975. PMID: 25966961. (IF: 2.3) |
| 4. Lou S, Lee HM, Qin H, Li JW, Gao Z, Liu X, Chan LL, Lam VKL, So WY, Wang Y, Lok S, Wang J, Ma RC, Tsui SK, Chan JC, Chan TF, Yip KY. Whole-genome bisulfite sequencing of multiple individuals reveals complementary roles of promoter and gene body methylation in transcriptional regulation. Genome Biol. 2014 Jul 30;15(7):408. PMID: 25074712. (IF: 9.2) (authors 7 out of 17) |